Compare CCRN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCRN | AUTL |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.7M | 388.6M |
| IPO Year | 2001 | 2025 |
| Metric | CCRN | AUTL |
|---|---|---|
| Price | $13.20 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $14.15 | $8.50 |
| AVG Volume (30 Days) | 493.1K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $816,484,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $5.01 | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $7.43 | $1.18 |
| 52 Week High | $14.98 | $2.70 |
| Indicator | CCRN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 74.08 | 52.98 |
| Support Level | $13.02 | $1.41 |
| Resistance Level | $13.23 | $1.73 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 57.14 | 81.67 |
Cross Country Healthcare Inc is a healthcare workforce solutions company delivering an AI-powered digital platform and advisory services to help health systems manage their labor ecosystem. It operates through two reportable segments: Nursing and Allied Staffing, which generates maximum revenue and provides staffing, recruiting, total talent solutions, vendor neutral programs, managed service programs, education healthcare services, caregiver services to PACE programs and outsourcing services; and Physician Staffing, which provides licensed practitioners including certified registered nurse anesthetists, nurse practitioners and physician assistants on temporary assignments. The company recruits professionals nationally and places them with healthcare facilities across the United States.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.